Anaplastic Oligodendroglioma Clinical Trial
Official title:
Phase I/II Study of Carboplatin, Melphalan and Etoposide Phosphate in Conjunction With Osmotic Opening of the Blood-Brain Barrier and Delayed Intravenous Sodium Thiosulfate Chemoprotection, in Previously Treated Subjects With Anaplastic Oligodendroglioma or Oligoastrocytoma
Verified date | March 2022 |
Source | OHSU Knight Cancer Institute |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This phase I/II trial studies the side effects and best dose of melphalan when given together with carboplatin, etoposide phosphate, mannitol, and sodium thiosulfate and to see how well they work in treating patients with previously treated brain tumors. Drugs used in chemotherapy, such as melphalan, carboplatin, and etoposide phosphate, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing, or by stopping them from spreading. Osmotic blood-brain barrier disruption (BBBD) uses mannitol to open the blood vessels around the brain and allow cancer-killing substances to be carried directly to the brain. Sodium thiosulfate may help lessen or prevent hearing loss and toxicities in patients undergoing chemotherapy with carboplatin and BBBD. Giving carboplatin, melphalan, etoposide phosphate, mannitol, and sodium thiosulfate together may be an effective treatment for brain tumors.
Status | Completed |
Enrollment | 33 |
Est. completion date | March 12, 2021 |
Est. primary completion date | March 12, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - Subjects with pathologic evidence of an anaplastic oligodendroglioma or mixed glioma (i.e. oligoastrocytoma) are eligible; histopathologic diagnosis will be made using World Health Organization classification criteria; to qualify as a mixed tumor there must be a minimum of 25% oligodendroglial element - Surgical procedure may have been complete resection, partial resection, or biopsy - Subjects must have had prior treatment with temozolomide; at least 28 days must have elapsed since completion of temozolomide or other chemotherapy - If subject has not undergone radiation therapy, then subject must have undergone prior consultation with a radiation oncologist (who is not an investigator on this study); if the subject has undergone radiation therapy, then at least 14 days must have elapsed since completion of radiation - Subjects performance status must be (Karnofsky performance status [KPS] greater than or equal to 50; Eastern Cooperative Oncology Group [ECOG] less than or equal to 2) - White blood cell count >= 2.5 x 10^3/mm^3 - Absolute granulocyte count > 1.5 x 10^3/mm^3 - Platelets >= 100 x 10^3/mm^3 - Serum creatinine < 1.5 x upper limit of normal - Bilirubin < 1.5 x upper limit of normal - Subjects baseline serum glutamic oxaloacetic transaminase (SGOT)/serum glutamate pyruvate transaminase (SGPT) must be < 2.5 x institutional upper limit of normal - Subjects must sign a written informed consent in accordance with institutional guidelines - The effects of carboplatin, melphalan and etoposide phosphate on the developing human fetus at the recommended therapeutic dose are unknown. For this reason and because these agents as well as other therapeutic agents used in this trial are known to be teratogenic. Sexually active women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study treatment and for the duration of study treatment; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately Exclusion Criteria: - Subjects with radiographic signs of excessive intracranial mass effect with associated rapid neurologic deterioration, and/or spinal cord block - Subjects at significant risk for general anesthesia - Subjects with uncontrolled (over the last 30 days) clinically significant confounding medical conditions - Subject is pregnant, has a positive serum human chorionic gonadotropin (hCG) or is lactating - Subjects who have contraindications to carboplatin, melphalan, etoposide phosphate, or sodium thiosulfate |
Country | Name | City | State |
---|---|---|---|
United States | University of Minnesota/Masonic Cancer Center | Minneapolis | Minnesota |
United States | OHSU Knight Cancer Institute | Portland | Oregon |
Lead Sponsor | Collaborator |
---|---|
OHSU Knight Cancer Institute | Oregon Health and Science University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | MTD of melphalan, defined as one dose level below the dose that produces grade 4 toxicity in 33% of patients, graded in accordance with National Cancer Institute Common Toxicity Criteria (NCI CTC) (version 3.0) (Phase I) | 4 weeks | ||
Primary | Overall survival | 1 year | ||
Primary | Progression free survival (Phase II) | Kaplan-Meier method will be used. 95% confidence intervals estimated. Cox proportional hazards regression models will be fit to explore potential predictors. | 1 year | |
Primary | Response rate | 1 year | ||
Primary | Time to best response | 1 year | ||
Secondary | Functional outcomes | Descriptive numeric and graphical summaries for functional status, quality of life, and cognitive function will be estimated for all subjects and separately for subjects with anaplastic oligodendrogliomas and oligoastrocytomas. | 1 year | |
Secondary | Incidence of severe neutropenia (specifically febrile neutropenia or sepsis) in accordance with NCI CTC (version 3.0) | Incidence rates of grade III/IV events and associated 95% confidence intervals will be estimated. | 1 year | |
Secondary | Rates of two year progression free survival (2YPFS) for specific tumor types | Separate estimates of 2YPFS and overall survival (and associated confidence intervals) will be made for subjects with anaplastic oligodendroglioma and for subjects with oligoastrocytoma. Confidence intervals will also be used to describe differences between this subject series and our earlier subject series. | 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01250470 -
Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma
|
Phase 1 | |
Active, not recruiting |
NCT00995007 -
A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas
|
Phase 2 | |
Recruiting |
NCT04541082 -
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
|
Phase 1 | |
Completed |
NCT00390299 -
Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme
|
Phase 1 | |
Completed |
NCT03043391 -
Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children
|
Phase 1 | |
Recruiting |
NCT03975829 -
Pediatric Long-Term Follow-up and Rollover Study
|
Phase 4 | |
Completed |
NCT02644291 -
Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors
|
Phase 1 | |
Completed |
NCT01847235 -
Temozolomide in Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: Single-arm, Phase II Trial
|
Phase 2 | |
Completed |
NCT01380782 -
BIBF 1120 for Recurrent High-Grade Gliomas
|
Phase 2 | |
Completed |
NCT01082926 -
Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2
|
Phase 1 | |
Completed |
NCT00362570 -
Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma
|
Phase 2 | |
Completed |
NCT03434262 -
SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors
|
Phase 1 | |
Completed |
NCT01316809 -
AZD8055 for Adults With Recurrent Gliomas
|
Phase 1 | |
Recruiting |
NCT04135807 -
Implantable Microdevice In Primary Brain Tumors
|
Early Phase 1 | |
Completed |
NCT01522820 -
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
|
Phase 1 | |
Completed |
NCT00884416 -
Sorafenib in Newly Diagnosed High Grade Glioma
|
Phase 1 | |
Active, not recruiting |
NCT02101905 -
Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma
|
Phase 1 | |
Recruiting |
NCT05698524 -
A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma
|
Phase 1 | |
Recruiting |
NCT01637753 -
Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Recurrent Malignant Glioma
|
N/A | |
Withdrawn |
NCT00734864 -
Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma
|
Phase 1 |